Results from analysis of clinical and tumor profiling data from ovarian cancer patients in the Clearity Foundation Data Repository were presented in two studies at the recent ASCO conference that took place June 1-5 in Chicago, Ill.
The first study
By: Deborah Zajchowski, PhD – Scientific Director, The Clearity Foundation
In the past three years, new hope has come to many women with ovarian cancer because of four new drugs that were approved for the treatment of this disease. These … Read more
By: Dr. Laura Shawver, Founder of The Clearity Foundation
Ten years ago, I was recovering from chemotherapy following my ovarian cancer diagnosis. As a scientist and a cancer drug developer, I knew the odds. I also knew that progress in … Read more
By: Cory Bentley, PhD
Many women diagnosed with ovarian cancer could probably write a dissertation for an advanced degree on ovarian cancer. Whether women are newly diagnosed or have recurrent ovarian cancer, the new learning needed to make informed decisions
By: Annette McElhiney
I love to paint and to see people enjoy themselves whenever possible. Because I have ovarian cancer, I’m also very committed to being an advocate. So what happens when you put all those things together? You give … Read more
Clearity has taken steps to help accelerate molecular matching by enabling women to access the drugs their physicians prescribe to treat their ovarian cancer. The pilot Clearity Match Patient Assistance program that was recently announced helps subsidize the cost of … Read more
By: Cory Bentley, PhD
The Society for Gynecological Oncology (SGO) Meeting this March in San Diego brought together physicians and scientists from all over the world to share the latest research, treatments, and thinking in gynecological cancers including ovarian. Clearity … Read more
The Clearity Foundation is proud to announce that our Scientific Advisory Board (SAB) Chair, Dr. Beth Karlan of Cedars-Sinai Medical Center, is the recipient of the 2016 Program Project Development Award. She submitted her work on the ‘Co-Evolution of … Read more
By: Laura Shawver
In 1998, Herceptin was approved for women with breast cancer whose tumors have extra copies of the Her2/ERBB2 gene and since that time, there have been more than 25 drugs approved to treat cancers with specific genetic … Read more
Check out Liz Laats’ amazing speech at Glitter and Glue for Good, not a dry eye in the house.
Thank you to everyone who joined us on March 7th for the inaugaural Glitter & Glue for Good event. More than … Read more
By: Cory Bentley, PhD
Bringing new treatments to ovarian cancer patients is very challenging. There are not as many patients diagnosed with this cancer as there are with other cancer types, such as breast, lung and colorectal, so there are … Read more
By Gordon Parry, PhD & Cory Bentley, PhD
The human immune system is very powerful. Successfully harnessing the immune system to destroy tumors, cancer immunotherapy, has been a dream of many oncologists. Cancer immunotherapy has become a reality with … Read more
By: Cory Bentley, PhD
Clearity first reported on drugs inhibiting PARP (Poly-ADP ribose polymerase), an important enzyme for tumor cell proliferation and survival, in its September 2010 patient newsletter. At that time, PARP inhibitors were just entering clinical trials and
… Read moreBy: Evan Friend, MD
The concept of maintenance therapy is based on the idea that by continuing treatment, patients will delay the time to subsequent recurrence or progression of the disease. Whether or not this therapy will lead to improved … Read more
By: Cory Bentley, PhD
Most ovarian cancer patients have become familiar with CA125 blood level monitoring, but trial drug DMUC5754A from Genentech puts a new twist on this familiar blood marker of advanced ovarian cancer. CA125 (cancer antigen 125) also … Read more
By: Cory Bentley, PhD & Teresa Gallagher, PhD
A study presented at the Society of Gynecological Oncology meeting found that most women diagnosed with ovarian cancer are not receiving medical care that meets the guidelines of the National Comprehensive Cancer … Read more
By: Cory Bentley, PhD & Teresa Gallagher, PhD
Ovarian cancer is a very diverse disease on the molecular level. Different tumors have different key molecular players and potentially different Achilles’ heels. Researchers are making real progress in pinpointing key players … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
